Genetic Factors Influencing Warfarin Dose

影响华法林剂量的遗传因素

• 批准号: 7018718
• 负责人: MARK J RIEDER
• 金额: $ 39.7万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-01-01 至 2008-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7018718
• 关键词: African American; bioinformatics; caucasian American; clinical research; clotting factor; drug administration rate /duration; drug metabolism; gene mutation; genetic mapping; human genetic material tag; molecular dynamics; nucleic acid amplification techniques; nucleic acid sequence; pharmacogenetics; pharmacokinetics; protein structure function; racial /ethnic difference; single nucleotide polymorphism; statistics /biometry; thromboembolism; tissue /cell culture; vitamin K; warfarin

DESCRIPTION (provided by applicant): The goal of this project is to apply pharmacogenomics to warfarin therapy, and gain new insights into the overall inter-individual genetic variation in response to this drug, so that prospective, individualized treatment with this anticoagulant becomes a reality. Warfarin is the most commonly employed oral anticoagulant used to treat thromboembolic disease and following surgery. One of the serious difficulties faced by physicians during both initiation of anticoagulation therapy and in determining a long-term maintenance dose is minimizing the risk of excessive bleeding. Consequently, patients have their prothrombin time (or international normalized ratio - INR) continuously monitored during the initiation phase of treatment and beyond. The ability to predict - a priori - the correct maintenance dose for an individual could be expected to revolutionize patient care and drastically cut healthcare costs. We have quantitated the effect of two critical genetic determinants of warfarin dose i.e. polymorphisms in the VKORC1 and CYP2C9 genes. Together with knowledge of patient age, sex, and concomitant drug medications, about 50% of the variability in warfarin dosing can now be accounted for in European ancestry populations, about 25% of which is due to genetic variants influencing expression of the VKORC1 gene. In this project, we propose to explore the relationship between single nucleotide polymorphisms (SNPs) in other key candidate genes and their association with warfarin maintenance dose. The long-term aim of this proposal is to account for 100% of the inter-individual variability in warfarin dosing.

描述(申请人提供)：该项目的目标是将药物基因组学应用于华法林治疗，并对该药物的整体个体间遗传变异获得新的见解，从而使这种抗凝剂的前瞻性、个体化治疗成为现实。华法林是最常用的口服抗凝剂，用于治疗血栓栓塞症和手术后。内科医生在开始抗凝治疗和确定长期维持剂量时面临的严重困难之一是将过度出血的风险降至最低。因此，患者在治疗开始阶段及以后持续监测他们的凝血酶原时间(或国际标准化比率-INR)。先验地预测个人正确的维持剂量的能力有望彻底改变患者护理，并大幅削减医疗成本。我们已经量化了华法林剂量的两个关键遗传决定因素的影响，即VKORC1和CYP2C9基因的多态。再加上对患者年龄、性别和相关药物的了解，华法林剂量的变异性现在约有50%可以在欧洲血统人群中解释，其中约25%是由于影响VKORC1基因表达的遗传变异。在这个项目中，我们打算探索其他关键候选基因的单核苷酸多态(SNPs)之间的关系，以及它们与华法林维持剂量的关系。这项建议的长期目标是100%解释华法林剂量的个体间差异。